AU Patent

AU2013355237C1 — PCSK9 iRNA compositions and methods of use thereof

Assigned to Alnylam Pharmaceuticals Inc · Expires 2022-09-22 · 4y expired

What this patent protects

The invention relates to RNAi agents,

USPTO Abstract

The invention relates to RNAi agents,

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: AU2013355237C1
Jurisdiction: AU
Classification: —
Expires: 2022-09-22
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.